These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3318450)

  • 21. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
    von Bergmann K; Leiss O
    Eur J Clin Invest; 1984 Apr; 14(2):150-4. PubMed ID: 6428905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time and dose study on the response of rats to the hypolipidaemic drug fenofibrate.
    Price SC; Hinton RH; Mitchell FE; Hall DE; Grasso P; Blane GF; Bridges JW
    Toxicology; 1986 Oct; 41(2):169-91. PubMed ID: 3764941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of combined hyperlipidaemia and its treatment with fenofibrate.
    Superko HR
    J Int Med Res; 1989; 17(2):99-112. PubMed ID: 2656334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
    Ziegler O; Drouin P
    Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM; Vega GL
    Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.
    Hahn SE; Goldberg DM
    Biochem Pharmacol; 1992 Feb; 43(3):625-33. PubMed ID: 1311585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of fibric acid derivatives (fibrates).
    Miller DB; Spence JD
    Clin Pharmacokinet; 1998 Feb; 34(2):155-62. PubMed ID: 9515185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
    Blane GF; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3737-46. PubMed ID: 7208340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and biochemical effects of fenofibrate.
    Kloer HU
    Am J Med; 1987 Nov; 83(5B):3-8. PubMed ID: 3318451
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.